A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy naive patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC): NVALT22

Authors :: Dingemans, A-M. C.
Ernst, S.
Mellema, W.
Burgers, S.
Staal-Van den Brekel, J.
Hendriks, L. E. L.
Hiltermann, T. J. N.
Van Walree, N.
Maas, K.
Youssef-ElSoud, M.
Biesma, B.
Van Noord, V.
Smit, E. F. F.
De langen, J. A.
Translational Immunology Groningen (TRIGR)
Source :: Annals of Oncology, 32(S5), S1327-S1327. Oxford University Press
Publication Year :: 2021

Tools